洛匹那韦/利托那韦治疗新型冠状病毒肺炎不良反应的观察分析  

Side effects of lopinavir/ritonavir for COVID-19

作　　者：盛皓宇[1] 全斌[1] 梁曼曼[1] 吴琼乐 杨江华[1] SHENG Haoyu;QUAN Bin;LIANG Manman;WU Qiongle;YANG Jianghua(Department of Infectious Diseases,Yijishan Hospital,Wannan Medical College,Wuhu 241001,Anhui,China)

机构地区：[1]皖南医学院弋矶山医院感染性疾病科,安徽芜湖241001

出　　处：《中国临床药理学与治疗学》2020年第11期1283-1287,共5页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：芜湖市科技攻关专项应急项目(2020dx1-1、2020dx1-2)。

摘　　要：目的:研究新型冠状病毒肺炎(COVID-19)患者使用洛匹那韦/利托那韦的不良反应的规律和特点。方法:对61例COVID-19确诊和疑似患者使用洛匹那韦/利托那韦片后发生药物不良反应的类型、一般资料、相关病史、预后等进行统计分析。结果:61例患者中41例(67.21%)发生与洛匹那韦/利托那韦相关不良反应,主要表现为消化道反应(82.93%)和肝功能损害(53.66%)。高龄、病程长、合并慢性胃肠道疾病是不良反应发生的独立危险因素。结论:洛匹那韦/利托那韦不良反应发生率高,可在密切观察患者症状和检测指标的前提下,用于COVID-19患者。特殊人群应用时要加强药学监护,确保用药安全。AIM:To study the regularity and characteristics of side effects of lopinavir/ritonavir for COVID-19.METHODS:The type of side effects,general information,medical history and prognosis in 61 confirmed and suspected COVID-19 patients with lopinavir/ritonavir were analyzed.RESULTS:Among the 61 patients,41(67.21%)had lopinavir/ritonavir related side effects,mainly manifested as gastrointestinal reactions(82.93%)and liver function damage(53.66%).Old age,long course of disease and chronic gastrointestinal disease are independent risk factors for side effects.CONCLUSION:Lopinavir/ritonavir has a high incidence of side effects and can be used in COVID-19 patients under the condition of close observation of the patient's symptoms and test results.Special population should improve pharmaceutical care to ensure the safety of drug use.

关 键 词：洛匹那韦/利托那韦 新型冠状病毒肺炎 药物不良反应 

分 类 号：R749[医药卫生—神经病学与精神病学]